Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
April 15, 2020 07:30 AM Eastern Daylight Time BOSTON – (BUSINESS WIRE) – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after […]
Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
BOSTON, Mass. – November 20, 2019 – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs […]
Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
November 12, 2018 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced preclinical results from its study of CRD-733, the company’s novel Phosphodiesterase-9 enzyme (PDE-9) inhibitor, in a poster presentation at the American Heart Association (AHA) […]
